22nd March 2021

Atnahs Appoints New Chief Financial Officer

Basildon (UK), 22 March 2021 – Atnahs has appointed Felipe Florez to the position of Chief Financial Officer (CFO), based in Switzerland. The new appointment is the beginning of an exciting new chapter for the rapidly expanding UK based company. His predecessor Alastair Hay has been promoted to Chief Business Development Officer (CBDO).

Felipe offers 20+ years of international senior management and board level experience at a variety of private and public companies. This includes a wealth of experience in Pharma, comprising branded, generics and over the counter medicines for companies such as Roche, Novartis, Allergan and STADA.

Dr Amit Patel, CEO of Atnahs explains, “We are delighted to welcome Felipe as a valued member of the senior management team. His international pharma experience will be invaluable in helping us to achieve our vision to become an agile and creative global specialty pharma business and preferred partner for innovator pharma companies.”

As CFO, Felipe will be drawing on his skills in strategic financial planning, cost tracking and analysis, portfolio optimisation, mergers and acquisitions and deal negotiations, amongst others. With direct experience across Europe(Italy, Germany, Switzerland, UK), U.S.A., Latin America (Colombia, Mexico, Venezuela), Middle East and Asia (China), he is well positioned to help further elevate Atnahs’ position globally.

Felipe adds, “I am excited to be joining at this time; Atnahs is expanding internationally, not only working with established brands but also investing in new. I have always enjoyed the fast-paced environment that Pharma offers and I’m looking forward to building, developing, leading and inspiring the Atnahs team to help both individuals and the company to perform at maximum potential.”

Felipe holds an MBA from the New York Institute of Technology and is Six Sigma Black Belt certified. 

Connect with Felipe on LinkedIn

About Atnahs
Atnahs is a specialty pharmaceutical business, focused on acquiring established branded medicines out of large cap and specialty pharma companies globally and developing its own niche medicines. Atnahs operates a portfolio of over 25 trusted brands and 2,000 SKUs across 140 markets, with a focus on therapeutic areas such as Cardiovascular, Women’s Health & Endocrinology, Neurology & Pain, and Gastroenterology & Oncology.